Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study

MEMBERS OF THE LIPIGEN STEERING COMMETTEE, Lorenzo Maria Vigo, José Pablo Werba

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is an inherited disorder characterized by high levels of blood cholesterol from birth and premature coronary heart disease. Thus, the identification of FH patients is crucial to prevent or delay the onset of cardiovascular events, and the availability of a tool helping with the diagnosis in the setting of general medicine is essential to improve FH patient identification.

METHODS: This study evaluated the performance of the Dutch Lipid Clinic Network (DLCN) score in FH patients enrolled in the LIPIGEN study, an Italian integrated network aimed at improving the identification of patients with genetic dyslipidaemias, including FH.

RESULTS: The DLCN score was applied on a sample of 1377 adults (mean age 42.9 ± 14.2 years) with genetic diagnosis of FH, resulting in 28.5% of the sample classified as probable FH and 37.9% as classified definite FH. Among these subjects, 43.4% had at least one missing data out of 8, and about 10.0% had 4 missing data or more. When analyzed based on the type of missing data, a higher percentage of subjects with at least 1 missing data in the clinical history or physical examination was classified as possible FH (DLCN score 3-5). We also found that using real or estimated pre-treatment LDL-C levels may significantly modify the DLCN score.

CONCLUSIONS: Although the DLCN score is a useful tool for physicians in the diagnosis of FH, it may be limited by the complexity to retrieve all the essential information, suggesting a crucial role of the clinical judgement in the identification of FH subjects.

Original languageEnglish
Pages (from-to)413-418
Number of pages6
JournalAtherosclerosis
Volume277
DOIs
Publication statusPublished - Oct 2018

Fingerprint

Hyperlipoproteinemia Type II
Lipids
Population
Premature Birth
Dyslipidemias
Hypercholesterolemia
Physical Examination
Coronary Disease
Medicine

Cite this

Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population : The LIPIGEN study. / MEMBERS OF THE LIPIGEN STEERING COMMETTEE ; Vigo, Lorenzo Maria; Werba, José Pablo.

In: Atherosclerosis, Vol. 277, 10.2018, p. 413-418.

Research output: Contribution to journalArticle

@article{165a8fc68cc24beb9b09851537e8f274,
title = "Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study",
abstract = "BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is an inherited disorder characterized by high levels of blood cholesterol from birth and premature coronary heart disease. Thus, the identification of FH patients is crucial to prevent or delay the onset of cardiovascular events, and the availability of a tool helping with the diagnosis in the setting of general medicine is essential to improve FH patient identification.METHODS: This study evaluated the performance of the Dutch Lipid Clinic Network (DLCN) score in FH patients enrolled in the LIPIGEN study, an Italian integrated network aimed at improving the identification of patients with genetic dyslipidaemias, including FH.RESULTS: The DLCN score was applied on a sample of 1377 adults (mean age 42.9 ± 14.2 years) with genetic diagnosis of FH, resulting in 28.5{\%} of the sample classified as probable FH and 37.9{\%} as classified definite FH. Among these subjects, 43.4{\%} had at least one missing data out of 8, and about 10.0{\%} had 4 missing data or more. When analyzed based on the type of missing data, a higher percentage of subjects with at least 1 missing data in the clinical history or physical examination was classified as possible FH (DLCN score 3-5). We also found that using real or estimated pre-treatment LDL-C levels may significantly modify the DLCN score.CONCLUSIONS: Although the DLCN score is a useful tool for physicians in the diagnosis of FH, it may be limited by the complexity to retrieve all the essential information, suggesting a crucial role of the clinical judgement in the identification of FH subjects.",
author = "{MEMBERS OF THE LIPIGEN STEERING COMMETTEE} and Manuela Casula and Elena Olmastroni and Angela Pirillo and Vigo, {Lorenzo Maria} and Werba, {Jos{\'e} Pablo} and Catapano, {Alberico Luigi}",
note = "Copyright {\circledC} 2018. Published by Elsevier B.V.",
year = "2018",
month = "10",
doi = "10.1016/j.atherosclerosis.2018.08.013",
language = "English",
volume = "277",
pages = "413--418",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population

T2 - The LIPIGEN study

AU - MEMBERS OF THE LIPIGEN STEERING COMMETTEE

AU - Casula, Manuela

AU - Olmastroni, Elena

AU - Pirillo, Angela

AU - Vigo, Lorenzo Maria

AU - Werba, José Pablo

AU - Catapano, Alberico Luigi

N1 - Copyright © 2018. Published by Elsevier B.V.

PY - 2018/10

Y1 - 2018/10

N2 - BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is an inherited disorder characterized by high levels of blood cholesterol from birth and premature coronary heart disease. Thus, the identification of FH patients is crucial to prevent or delay the onset of cardiovascular events, and the availability of a tool helping with the diagnosis in the setting of general medicine is essential to improve FH patient identification.METHODS: This study evaluated the performance of the Dutch Lipid Clinic Network (DLCN) score in FH patients enrolled in the LIPIGEN study, an Italian integrated network aimed at improving the identification of patients with genetic dyslipidaemias, including FH.RESULTS: The DLCN score was applied on a sample of 1377 adults (mean age 42.9 ± 14.2 years) with genetic diagnosis of FH, resulting in 28.5% of the sample classified as probable FH and 37.9% as classified definite FH. Among these subjects, 43.4% had at least one missing data out of 8, and about 10.0% had 4 missing data or more. When analyzed based on the type of missing data, a higher percentage of subjects with at least 1 missing data in the clinical history or physical examination was classified as possible FH (DLCN score 3-5). We also found that using real or estimated pre-treatment LDL-C levels may significantly modify the DLCN score.CONCLUSIONS: Although the DLCN score is a useful tool for physicians in the diagnosis of FH, it may be limited by the complexity to retrieve all the essential information, suggesting a crucial role of the clinical judgement in the identification of FH subjects.

AB - BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is an inherited disorder characterized by high levels of blood cholesterol from birth and premature coronary heart disease. Thus, the identification of FH patients is crucial to prevent or delay the onset of cardiovascular events, and the availability of a tool helping with the diagnosis in the setting of general medicine is essential to improve FH patient identification.METHODS: This study evaluated the performance of the Dutch Lipid Clinic Network (DLCN) score in FH patients enrolled in the LIPIGEN study, an Italian integrated network aimed at improving the identification of patients with genetic dyslipidaemias, including FH.RESULTS: The DLCN score was applied on a sample of 1377 adults (mean age 42.9 ± 14.2 years) with genetic diagnosis of FH, resulting in 28.5% of the sample classified as probable FH and 37.9% as classified definite FH. Among these subjects, 43.4% had at least one missing data out of 8, and about 10.0% had 4 missing data or more. When analyzed based on the type of missing data, a higher percentage of subjects with at least 1 missing data in the clinical history or physical examination was classified as possible FH (DLCN score 3-5). We also found that using real or estimated pre-treatment LDL-C levels may significantly modify the DLCN score.CONCLUSIONS: Although the DLCN score is a useful tool for physicians in the diagnosis of FH, it may be limited by the complexity to retrieve all the essential information, suggesting a crucial role of the clinical judgement in the identification of FH subjects.

U2 - 10.1016/j.atherosclerosis.2018.08.013

DO - 10.1016/j.atherosclerosis.2018.08.013

M3 - Article

C2 - 30270079

VL - 277

SP - 413

EP - 418

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -